+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Fibroblast Growth Factor 2 - Pipeline Review, H2 2019

  • ID: 4866536
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 63 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Anaeropharma Science Inc
  • Aurealis Therapeutics AG
  • ID Pharma Co Ltd
  • NeuBase Therapeutics Inc
  • Ribomic Inc
  • Zucero Therapeutics Ltd
  • MORE
Fibroblast Growth Factor 2 - Pipeline Review, H2 2019

Summary

According to the recently published report 'Fibroblast Growth Factor 2 - Pipeline Review, H2 2019'; Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) pipeline Target constitutes close to 10 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Basic fibroblast growth factor also known as bFGF or FGF2 is a member of the fibroblast growth factor family. This protein plays an important role in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. Diseases associated with FGF2 include corneal neovascularization and pulmonary capillary hemangiomatosis.

The report 'Fibroblast Growth Factor 2 - Pipeline Review, H2 2019' outlays comprehensive information on the Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Ophthalmology, Cardiovascular, Central Nervous System, Dermatology, Immunology, Musculoskeletal Disorders and Respiratory which include indications Critical Limb Ischemia, Wet (Neovascular / Exudative) Macular Degeneration, Achondroplasia, Angina (Angina Pectoris), Bone Disorders, Cancer Pain, Choroidal Neovascularization, Diabetic Foot Ulcers, Diabetic Macular Edema, Diabetic Retinopathy, Hepatocellular Carcinoma, Idiopathic Pulmonary Fibrosis, Intermittent Claudication, Lung Cancer, Melanoma, Metastatic Pancreatic Cancer, Osteoporosis, Pancreatic Cancer, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Peripheral Artery Occlusive Disease (PAOD), Proliferative Diabetic Retinopathy (PDR), Retinal Vein Occlusion, Rheumatoid Arthritis, Solid Tumor and Venous Leg Ulcers (Crural Ulcer).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2)
  • The report reviews Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Anaeropharma Science Inc
  • Aurealis Therapeutics AG
  • ID Pharma Co Ltd
  • NeuBase Therapeutics Inc
  • Ribomic Inc
  • Zucero Therapeutics Ltd
  • MORE
Introduction
Report Coverage
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Overview
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Companies Involved in Therapeutics Development
Anaeropharma Science Inc
Aurealis Therapeutics AG
ID Pharma Co Ltd
NeuBase Therapeutics Inc
Ribomic Inc
Yantai RC-Pharmaceutical Co Ltd
Zucero Therapeutics Ltd
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Drug Profiles
AUP-16 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DVC-10101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Inhibit FGF-2 for Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate FGF2 for Critical Limb Ischemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oncolytic Virus to Activate FGF2 for Pancreatic Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pixatimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBM-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RC-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
squalamine lactate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TR-764 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Dormant Products
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Discontinued Products
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Product Development Milestones
Featured News & Press Releases
Jun 19, 2019: Ribomic reports positive results from SUSHI study of RBM-007
Jun 03, 2019: Publication of a collaborative study with Keio University School of Medicine on the inhibitory effect of RBM-007 combination therapy on Lung Cancer
Jan 05, 2018: Ohr Pharmaceutical Announces Efficacy Results from the MAKO Study in Wet-AMD
Sep 24, 2017: Aurealis Pharma to Present at Sachs Associates 17th Annual Biotech in Europe Forum Basel, September 26-27t h 2017
Apr 26, 2017: Aurealis Pharma to Discuss AUP-16 Clinical Development at the 27th European Wound Managament Association Annual Meeting, Amsterdam
Apr 10, 2017: Ohr Pharmaceutical Provides Update on Ongoing Squalamine Clinical Trial in Wet-AMD
Jan 02, 2017: Aurealis Pharma to Attend 9th Annual Partnering Conference - Biotech Showcase, San Francisco
Sep 23, 2016: Aurealis Pharma to Present at Sachs Associates 16th, Annual Biotech in Europe Forum Basel
May 02, 2016: Ohr Pharmaceutical Announces Appointment of David Brown, MD as Chair of Phase 3 Clinical Program Steering Committee
Apr 27, 2016: Ohr Pharmaceutical Announces Presentation on Squalamine Lactate at the 2016 Association for Research in Vision and Ophthalmology Conference in Seattle, WA
Apr 18, 2016: Ohr Pharmaceutical, Inc. Announces Enrollment of First Patient in Phase III Wet AMD Clinical Program
Mar 29, 2016: Ohr Pharmaceutical, Inc. Announces SPA Agreement with US FDA and Initiation of Phase III Wet AMD Clinical Program
Nov 16, 2015: Ohr Pharmaceutical Presents New Data From OHR-102 Phase II IMPACT Study in Wet-AMD at American Academy of Ophthalmology Annual Meeting
Nov 12, 2015: Ohr Pharmaceutical Announces Submission of a Special Protocol Assessment and Upcoming Presentation on OHR-102 at American Academy of Ophthalmology
Sep 04, 2015: Aurealis Pharma Expands its Management Team and Announces Opening of New Office In Basel Switzerland
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Anaeropharma Science Inc, H2 2019
Pipeline by Aurealis Therapeutics AG, H2 2019
Pipeline by ID Pharma Co Ltd, H2 2019
Pipeline by NeuBase Therapeutics Inc, H2 2019
Pipeline by Ribomic Inc, H2 2019
Pipeline by Yantai RC-Pharmaceutical Co Ltd, H2 2019
Pipeline by Zucero Therapeutics Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Anaeropharma Science Inc
  • Aurealis Therapeutics AG
  • ID Pharma Co Ltd
  • NeuBase Therapeutics Inc
  • Ribomic Inc
  • Yantai RC-Pharmaceutical Co Ltd
  • Zucero Therapeutics Ltd
Note: Product cover images may vary from those shown
Adroll
adroll